Skip to content Skip to sidebar Skip to footer
Menu
Menu
Newsletter
Menu
Newsletter
Bio Gene Technology ASX:BTG)
Agriculture Stocks Penny Stocks Small Caps Stocks Undervalued Stocks
Bio Gene Technology (ASX:BGT): Commercialising a new class of insecticides
Bio Gene Technology (ASX:BGT) ASX-listed AgTech company developing two compounds - Flavocide™ and Qcide™ - as insecticides. Investors may hear the word insecticide and think that Flavocide™ and Qcide™ are just another couple of consumer insect sprays (such as Mortein) and wonder whether the market really needs it. How can Bio Gene's compounds stand out…
September 9, 20240Comments
Paradigm Biopharmaceuticals
Healthcare Stocks
Paradigm Biopharmaceuticals (ASX:PAR): An osteoarthritis solution that could hit the market within 3 years
If you thought the were plenty of treatments for osteoarthritis already, Paradigm Biopharmaceuticals (ASX:PAR) is a company that has something to say about that.You see, any ‘treatments’ that exist are only about addressing the pain or other symptoms rather than being a cure or remission. These treatments tend to need frequent administration or lose effectiveness…
September 6, 20240Comments
Cann Group
Agriculture Stocks Cannabis Stocks Healthcare Stocks Mid Cap Stocks Small Caps Stocks
Cann Group (ASX:CAN): Successfully producing GMP medicinal cannabis since 2017
Cann Group (ASX:CAN) is the first company in Australia that was issued a medicinal cannabis license, granted by the Australian Government's Office of Drug Control in March 2017.During this time, there have been various busts and booms in the cannabis sector, although there has been little hype since the aftermath of TGA's declassification of certain…
September 6, 20240Comments
Percheron Therapeutics
Healthcare Stocks
Percheron Therapeutics (ASX:PER): Releasing Phase II data by the end of CY24, and successful data could lead to a major re-rate
It has been less then a year since Antisense Therapeutics changed its name to Percheron Therapeutics (ASX:PER). It is common for biotech companies to change their name when they pivot to new indications and/or to new assets, but this was not the case with Percheron. It is still focused on Duchenne Muscular Dystrophy (DMD), a…
September 3, 20240Comments
Qantas' capex
Airlines
Qantas’ capex bill: The company is coping with a $12bn+ bullet for now, but will it eventually bite shareholders?
Qantas' capex needs are bubbling under the surface, but have not gone away. Former CEO Alan Joyce's tenure came to an unceremonious end last year. There have been many criticisms of his tenure including centralisation of decision-making around himself, his using of the airline for social causes and relations with employees, both mainline staff and…
September 2, 20240Comments
Proteomics International Laboratories
Healthcare Stocks
Proteomics International Laboratories (ASX:PIQ): It thinks its got a great DKD detection test, but do regulators agree?
Proteomics International Laboratories (ASX:PIQ) is one of the larger companies that will be presenting at next month's Life Sciences Conference. Capped at over $100m, its flagship product is PromarkerD, a predictive test for Diabetic Kidney Disease (DKD). Like all up and coming healthcare stocks, it has a great idea, but execution is the key. And…
August 28, 20240Comments

the Kick-ass Multipurpose WordPress Theme

Investing in the Year of the Rat
2020, the Golden Year
Market trouble spots to avoid in 2020
© 2026 Kicker. All Rights Reserved.

Add Your Heading Text Here